Article

# Enhancing the cell-free expression of native membrane proteins by *in-silico* optimisation of the coding sequence - an experimental study of the human voltage-dependent anion channel

Sonja Zayni <sup>1</sup>, Samar Damiati <sup>2</sup>, Susana Moreno-Flores <sup>3</sup>, Fabian Amman <sup>4\*</sup>, Ivo Hofacker <sup>4,5</sup> and Eva-Kathrin Ehmoser <sup>1\*</sup>

- Department of Nanobiotechnology, Institute for Synthetic Bioarchitectures, University of Natural Resources and Life Sciences, Vienna (BOKU), Muthgasse 11, A-1190 Wien, Austria; sonja.zayni@boku.ac.at
- <sup>2</sup> Department of Biochemisty, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia; sdamiati@kau edu sa
- <sup>3</sup> Dr. Susana Moreno-Flores, E-mail: smf8097@gmail.com
- Institute for Theoretical Chemistry Theoretical Biochemistry Group, University of Vienna, Währinger Straße 17, A-1090 Wien, Austria; ivo@tbi.unive.ac.at
- <sup>5</sup> Research Group Bioinformatics and Computational Biology, Faculty of Computer Science, University of Vienna, Währinger Straße 29, A-1090 Wien, Austria
- \* Correspondence: F.A.: fabian@tbi.univie.ac.at; E.E.: eva.ehmoser@boku.ac.at

**Abstract:** The investigation of membrane proteins, key constituents of cells, is hampered by the difficulty and complexity of their *in vitro* synthesis, of unpredictable yield. Cell-free synthesis is herein employed to unravel the impact of the expression construct on gene transcription and translation, without the complex regulatory mechanisms of cellular systems. Through the systematic design of plasmids in the immediacy of the start of the target gene, it was possible to identify translation initiation and the conformation of mRNA as the main factors governing the cell-free expression efficiency of the human voltage dependent anion channel (VDAC), a relevant membrane protein in drug-based therapy. A simple translation initiation model was developed to quantitatively assess the expression potential for the designed constructs. A scoring function is proposed that quantifies the feasibility of formation of the translation initiation complex through the ribosome-mRNA hybridization energy and the accessibility of the mRNA segment binding to the ribosome. The scoring function enables to optimize plasmid sequences and semi-quantitatively predict protein expression efficiencies. This scoring function is publicly available as webservice XenoExpressO at rna.tbi.univie.ac.at.

**Keywords:** cell-free membrane protein expression; translation enhancer; translation initiation; ribosome docking site; sequence design.

# 1. Introduction

Understanding structure and function of membrane proteins is key in many biological processes, yet faces numerous issues. Membrane proteins are notoriously difficult to synthesise: in cells, membrane proteins are usually expressed in low amounts, and their expression profile is heavily controlled as part of regulatory processes. Besides, in-cell expression of recombinant membrane proteins only works for those proteins that do not significantly alter the physiology of their hosts. The characterisation of membrane proteins is no less difficult: the structural integrity of membrane proteins is hard to preserve in extracellular conditions, and function may be lost if proteins are removed from their native membranes.

The production of membrane proteins outside living cells circumvents many of the issues of in-cell synthesis [1,2]. Cell-free synthesis uses cell lysates to *in situ* generate rightly

folded membrane proteins [3, 4] from exogeneous mRNA or DNA, which can be directly incorporated into artificial membranes [5].

Yet cell-free and in-cell synthesis face a common challenge. In both the design of the plasmid vector is crucial. This genetic construct lodges the sequences of the transcription promotor, of the ribosomal binding site, RBS, and occasionally of translation enhancers in addition to the target gene [1, 6]. The sequence layout, particularly in the vicinity of the gene's initiation or start codon, has become the quintessence of cell-free protein expression and yet it has not been fully exploited in optimizing constructs for protein expression. The coding region adjacent to the start codon remains untapped in both *in-silico* [7, 8] and wetbench design of constructs, and finding a working construct is to date mainly based on trial and error.

Herein we present a rationalized approach to the generation of constructs for the expression of wild-type, human membrane proteins in prokaryotic cell-free systems, that includes alterations in the coding sequence proximal to the start codon. As a relevant case example, we chose the human voltage dependent anion channel or VDAC; a small, 285-amino acid-long protein (M<sub>w</sub>=31 kDa), that is predominantly found in the mitochondrial outer membrane <sup>[9, 10]</sup>. VDAC forms cylindrical channels across the membrane of diameter 20–30 Å, allowing the passage of ions and small molecules <sup>[11, 12, 13]</sup>, and is involved in various pathophysiological mechanisms.

# 2. Materials and Methods

Cloning and purification of plasmids. Cloning was performed with Gateway® recombination cloning technology (Invitrogen, Thermo Fisher Scientific, Waltham USA). Eight forward and one reverse primers were designed, see [14]. The DNA of VDAC (855 base pairs), was amplified by PCR (Biometra Thermocycler, Analytik Jena, Jena DE), with Phusion DNA polymerase (Thermo Fisher) and vector pQE30-VDAC as template. All PCR products were purified with the MinElute PCR purification kit (Qiagen, Venlo, NL). Gateway® recombination was performed with enzyme mixes BP Clonase II and LR Clonase II according to manufacturer's instructions (Invitrogen, Thermo Fisher Scientific). BP reactions were carried out with the purified fragments and the entry vector pDONR221. LR reactions were performed with entry clones from individual bacterial colonies and destination vectors pDEST14 and pDEST17. BP and LR products were subsequently transformed into *E. coli* strains DH5α and Top 10 (Invitrogen). Positive clones were identified by in situ PCR (RedTaq Master Mix, Sigma-Aldrich, St Louis, USA). Plasmid DNA was then purified with the QIAprep Spin Miniprep Kit (Qiagen) and examined through digestion with restriction enzymes EcoRI/HindIII and PstI/Xhol for DONR and DEST vector constructs, respectively (Termo Fisher). Sequencing of VDAC gene inserts for DONR and DEST vectors was performed with the VDAC specific and T7 promotor/T7 terminator primers (LGC Genomics, Berlin, DE; Microsynth, Balgach, CH), respectively. Plasmids were purified with Midi preps (Qiagen Plasmid Midi Kit or innu PREP Plasmid MIDI Direct Kit, Analytik Jena).

Cell-free synthesis. Reactions were performed with two different kits, the S30 T7 High-yield protein expression system (Promega, Fitchburg, USA) and the PURExpress<sup>R</sup> in Vitro Protein Synthesis Kit (New England BioLabs, Ipswich, USA) according to the manufacturer's instructions. The results herein reported refer to those obtained with the second kit, as it proved the most effective. 250 ng of plasmid, 0.2  $\mu$ l Ribonuclease inhibitor (RNasin, Promega) and 0.4  $\mu$ l of FluoroTect TM Green<sub>Lys</sub> were added to PURExpress extracts to a reaction volume of 10  $\mu$ l. After a 2 hour incubation step at 37°C, 10  $\mu$ l of sample dilution buffer (LDS sample buffer reducing agent, Invitrogen, Thermo Fisher) was added to the mixture. Protein denaturation in the diluted samples was conducted at 70°C for 10 min before electrophoresis.

SDS-Page and Western Blot. The denatured samples were loaded into 10% precast gels (Invitrogen, Thermo Fisher). Electrophoresis was conducted at a constant potential of


200V for 45 minutes and imaged immediately after with a Safe Imager 2.0TM Blue Light Transilluminator. The emission fluorescence at ~470 nm of the fluorescent lysine accounted for the optical visualisation of the protein bands. Two identical acrylamide gels were prepared: 1. for the staining procedure: Coomassie staining was performed with SimplyBlueTM SafeSTain solution (Invitrogen Thermo Fisher) 2. For western blotting: after electromediated proteintransfer from the gel to PVDF membrane (iBlot®, Thermo Fisher) immunodetection of proteins was carried out in an InfraRed Imager (Odyssey® Infrared Imaging System, LI-COR Biosciences, Lincoln, USA), using rabbit monoclonal anti-VDAC (Cell Signaling Technology, Cambridge, UK), or anti- 6x HIS-tag (Gen Tex) as primary antibody, and goat anti-rabbit IRDye 680 (LI-COR) as secondary antibody. PageRulerTM Plus Prestained Protein Ladder (Thermo Fisher) were used as standard.

RNA detection and quantitative PCR (qPCR). Levels of RNA were measured with a ND-10000 Spectrophotometer (Nanodrop Technologies, Wilmington USA) on RNA-isolated samples [14]. For qPCR, ~650 ng of isolated RNA was reversed-transcribed into cDNA with the iScript TM Select cDNA synthesis kit and random primers (Bio-Rad, Hercules, USA). qPCR was performed in a 48-well, MiniOpticon Real-Time PCR System (Bio-Rad) on sample triplicates (20 µl total reaction volume) [14]. SsoAdvancedTM Universal SYBR Green Supermix (Bio-Rad) was used to prepare the master mix for each primer.

Calculation of  $\delta$  and in-silico optimization of mRNA constructs. Hybridization and opening energies,  $\Delta$ EsD and  $\Delta$ Eopen, were calculated with RNAduplex and RNAup, respectively [15, 16].  $\Delta$ EtRNA is added as a stabilizing constant, -1.19 kcal/mol or -0.075 kcal/mol only for start codons AUG or GUG, respectively. Optimisation is conducted with a self-devised simulated annealing algorithm that performs, selectively accepts and characterises random single-nucleotide swaps in source transcripts.  $\Delta$ Eopen(i) for single and sets of constructs, respectively, were calculated with RNAplfold from genome sequences available at microbes.uscs.edu and ensemble biomart [14, 17].

### 3. Results

The design of constructs is such that enables not only to assess the influence of expression modulators on protein expression efficiency, but also to assign their optimal location upstream and downstream in relation to the initiation codon. The generation of constructs was accomplished by the recombination of a PCR-product into commercially available plasmids. Consequently, the PCR-product starts with a specific nucleotide sequence, called *primer*. The target sequence in our example is represented by the VDAC-encoding gene. By the introduction of various self-designed primers we are able to modify the genetic code in a controlled fashion and hence assess the effect of these modifications on protein expression. The original pDEST17 plasmids provide sequences before (upstream) and after (downstream) the ATG codon in the untranslated and translated regions, 5'UTR and TR, respectively (figure 1a). The UTR is preceded by the T7 promoter and lodges a prokaryotic RBS in the form of a Shine-Dalgarno (SD) sequence. The TR starts with a 26-amino acid-long sequence containing a 6x HIS-tag (figure 1b). pDEST17 allows the insertion of the PCR-product right after this sequence in the TR. Consequently, the 5'UTR and the location of the RBS is fixed.




**Figure 1**. The nucleotide sequence pf PDEST17-based plasmids in the proximity of the start codon (a), primer library (b), expression levels (SDS-page gel fluorescence scan) (c); nc: negative (no plasmid) control

Figure 1c shows that pDEST17-based constructs (VDAC-I) enable protein expression, and alterations in the genetic code far downstream the start codon have no significant effect on protein expression efficiency. The SDS-page gel and Western Blot [18] of the reaction mixture after protein expression with constructs VDAC-I-A and VDAC-I-B and in the presence of fluorescent lysine, display a single band at approx. 39 kDa of similar intensity. This is indicative of similar expression levels of a single protein. Protein characterisation via MALDI-TOF mass spectrometry of trypsin-digested protein fragments, reveal that 34% of the peptides match VDAC sequences, which proves sufficient to confirm the primary structure of VDAC [19]. The insertion of the chloramphenical acetyltransferase (CAT)-enhancer sequence [20], as in VDAC-I-C, does not significantly increase the level of protein expression. The results point to the HIS-tag-containing sequence, possibly in combination with the RBS-starting sequence, as the essential cause for VDAC expression.

Our first hypothesis sets the length and nature of the untranslated region between the T7 promoter and the start codon, the 5′ UTR, as decisive in gene transcription and translation, and we thus employed the plasmid pDEST14 to gain better control over this region, while aiming to express native, tag-free VDAC at comparable levels to those attained through pDEST17-based constructs. pDEST14 provides the T7 promoter as its pDEST17 counterpart does but, unlike the latter, it allows the insertion of self-designed primers at desired locations upstream and downstream the start codon.


Figure 2 shows the primer sequences of the pDEST14-based constructs (VDAC-II) and their respective VDAC expression levels. Though the primer sequences of VDAC-II-A and VDAC-II-B are in turn identical to those of VDAC-I-A and VDAC-I-B, there is hardly evidence of protein expression, as shown by the examplry SDS-page gel fluorescence scan (figure 2c) and the corresponding Western Blot [18]. This evinces the enhancer role of the pre-VDAC sequence and the 5'UTR in pDEST17-based plasmids.



**Figure 2**. The nucleotides sequence of pDEST14-based plasmids in the proximity of the start codon (a); primer library (b), expression levels (SDS-page gel fluorescene scan)(c); nc: negative (no plasmid) control

In view of these results, we directed our efforts in investigating the role of the 5'UTR and the adjacent TR in protein expression. Starting at the SD sequence, we inserted the 5'UTR of the pDEST17 vector into pDEST14-based constructs at the same location. The resulting construct, VDAC-II-C, enables marginal protein expression, as evinced by the appearance of a weak band *above* 36 kDa (figure 2c) [18]. So does the construct VDAC-II-D, with the same first three-codon-long coding sequence of the pDEST17 vector. Only the insertion of the 4-codon-long CAT-enhancer sequence after the start codon, as in VDAC-II-E and F, increases the levels of protein expression, irrespectively of the 5'UTR choice. In this case however, VDAC expression is enhanced at the expense of capping the N-terminus of the protein sequence with the non-native amino acid sequence EKKI.

At this point it is crucial to consider whether cell-free VDAC expression is hampered at the transcriptional or translational level. Should gene transcription determine protein expression, mRNA levels would be significantly higher in those cases where protein is expressed, than in those where expression is marginal or not detected. In other words, any changes in levels of transcription by T7 polymerase should result in changes in levels of protein expression. Fig.3 shows that this is not the case; quantitative PCR (Cq values) of cDNA derived from transcripts of different plasmids evince similar levels of mRNA, irrespectively of the plasmid's translatability, cDNA dilution, and choice of PCR-primer pairs. This and the previous results suggest translation, in particular translation initiation rather than transcription, as the decisive step in determining protein expression, which reverts the focus on the transcript sequence in the immediacy of the start codon.




**Figure 3**. mRNA transcription levels (quantitation cycles, Cq) of different plasmids. Real-time amplification of 3 different dilutions of the as-obtained reverse-transcripted cDNA (a: 1:10; b: 1:100; c: 1:1000) with 3 different primer pairs (1,2, and 3). Right: Cq values for the negative (no plasmid) control.

In contrast to eukaryotic-based expression systems, the prokaryotic machinery is not capable of clearing conformational elements of mRNA that may potentially hamper the correct assembly of the ribosome and hence of the initiation complex. [22,23] Although the specificity of the interaction between ribosome and mRNA is mediated by hybridization of the SD sequence and strengthened by the coupling of the first transfer-RNA (tRNA Met) to the start codon, the whole initiation complex extends over a much longer nucleotide segment. This segment or ribosome docking site (RDS) extends over 30 nucleotides downstream the SD sequence [7]. Since SD sequences are usually positioned 5-13 nucleotides before the start codon [22], the RDS extends into the coding sequence. Based on this fact, we changed our strategy of ameliorating constructs and opted for a quantitative approach. Inspired by the work of Na *et al.* [7], we developed a simple *in-silico* translation-initiation potential model to quantify the likelihood of translation of a given mRNA sequence from a series of interaction energy parameters. The model defines the translation-initiation potential  $\delta$  as

$$\delta = exp^{\left(-\left(^{\Delta E_{SD} + \Delta E_{tRNA} + \Delta E_{open}}/_{RT}\right)\right)}$$

where R is the Boltzmann constant, T the temperature,  $\Delta E_{\text{SD}}$  the hybridization energy between the SD and anti-SD sequences,  $\Delta E_{\text{tRNA}}$  the hybridization energy of the start codon and its respective anti-codon (i.e, the tRNA<sup>Met</sup>), and  $\Delta E_{\text{open}}$  the energy required to unfold the 30-nucleotide-long RDS. Here,  $\Delta E_{\text{SD}}$  and  $\Delta E_{\text{tRNA}}$  are constant since neither the SD nor the start codon are altered. Consequently, variations in  $\delta$  are exclusively determined by  $\Delta E_{\text{open}}$ . Applying the model to the plasmids under study enabled us to rationalise translation events, as translatable constructs consistently scored higher  $\delta$ , or lower  $\Delta E_{\text{open}}$ , than non-translatable ones. Figure 4a shows  $\Delta E_{\text{open}}$  as a function of the position of the SD sequence relative to the start codon, i. The graph displays a minimum at about 11 nucleotides upstream from the start codon only in the case of translatable plasmids (figure 4a). The deeper the minimum, the likelier the occurrence of protein expression.

In view of these results,  $\Delta E_{open}$  was used as scoring function in a simulated-annealing algorithm to obtain a sequence that maximises the accessibility of the RDS, preserves the 5′UTR and the native VDAC-coding sequence. Henceforth, we exploited the redundancy of the genetic code by introducing single-nucleotide, synonymous mutations in the VDAC-coding sequence. Applying the optimisation algorithm on VDAC-II-A results in the construct VDAC-II-G, sporting seven synonymous mutations in the first nine TR codons. VDAC-II-G encodes the wild-type amino acid sequence of VDAC, and displays a low value of  $\Delta E_{open}$  at the right location (figure 4a). Figure 2c shows that VDAC-II-G experimentally enables protein expression in a comparable degree to those attained with enhancer-containing sequences.



**Figure 4**.  $\Delta E_{\rm open}$  (i) to unfold the 30-nucleotide-long RDS starting at location i with respect to the start codon (i=0). a) Translatable (VDAC-II-F,G, VDAC-I-A) and not-translatable constructs (VDAC-II-A) for VDAC expression. b) Average  $\Delta E_{\rm open}$  (i) for pDEST14 constructs of all human membrane proteins with and without expression enhancers, and after coding sequence optimization with synonymous mutations. Dotted lines depict the values of  $\Delta E_{\rm open}$  at i=-11 for the human and *E.coli* genomes.

Cell-free protein synthesis is governed by the biochemical conditions and the template DNA sequence. The *E. coli*-based system used in this study requires high concentrations of phage T7-RNA polymerase and a surplus of fast degradable amino acids, such as arginine, cysteine, tryptophan, glutamate, aspartate, and methionine. [24, 25] Though necessary, these conditions are not as crucial in protein expression as the mRNA sequence, or rather, the mRNA conformational structure. Sequence elements in the proximity of the start codon, either upstream or downstream, are known to significantly affect translation efficiency. [26, 27, 28] Which not only implies finding the optimal location for the RBS, [29] but also proper tailoring of the whole RDS. Our findings are based on the design of several plasmids in which the sequence in the immediacy of the start codon have been altered to accommodate the RBS and the gene of a membrane protein at varying distances upstream and downstream the start codon, respectively. The results so far indicate that the best strategy to elicit tag-free protein expression from constructs with off-the-shelf RBSs in prokaryotic cell-free expression systems entails proper engineering of the TR proximal to the initiation codon.

Translation initiation in prokaryotes differs from that of eukaryotes in that it involves much less molecular factors and is significantly less complex. As pointed above, prokaryotes lack mRNA unfolding mechanisms that facilitate the formation of the translation initiation complex, and hence are expected to rely on low- $\Delta E_{open}$  transcripts to ensure the expression of their genes. Indeed,  $\Delta E_{open}$  at i ~ -11 is significantly lower for transcripts of the *E. coli* genome than for those of the human genome. [30] On the other hand, upregulation mechanisms for protein expression in prokaryotic cells are not present in cell-free systems, and may be responsible for in-cell expression of recombinant VDAC from plasmids that do not elicit expression otherwise. [31] Hence, the mRNA sequence is crucial in the cell-free context. Since the ribosome footprint on the mRNA sequence is larger than the RBS and extends well into the TR, a correspondingly long mRNA segment should be

accessible for the ribosome to properly dock at and initiate translation. Hence, it makes sense to modify the mRNA sequence within the proximal TR so as to prevent the formation of hindering conformations and gain full access to the RDS. A low  $\Delta E_{open}(-11)$  can thus be viewed as a *sine qua non* criterion for cell-free protein expression with a prokary-otic machinery. According to figure 4a, the efficiency in VDAC expression varies with the nature of the construct as follows: I-A > II-F  $\cong$  II-G >> II-A. A trend that has been qualitatively confirmed by the experiments (figures 1c and 2c).

In this line, the role of translation enhancers in constructs with prokaryotic-like UTRs can be explained. Inserting human genes into pDEST14 vectors alone does not result in values of  $\Delta E_{open}$  low enough to allow expression (figure 4b, red curve). Contrarily, the insertion of the 6xHIS-tag or the CAT enhancer nucleotide sequences significantly reduces  $\Delta E_{open}$  to similar or lower values than those of *E. coli* transcripts (figure 4b, blue and purple curves). Enhancers thus enable membrane protein expression inasmuch as they facilitate ribosome assembly through a less structured mRNA in the proximal TR.

Though both enhancers appear as valid options for constructs with poor translation efficiency, they may not be so in those cases where proteins with bare N-termini and native amino acid sequences are required  $^{[32]}$ . Fortunately, the redundancy of the genetic code provides enough maneuverability to reduce  $\Delta E_{\rm open}$  without altering the amino acid sequence, as shown in the case of VDAC. A potentially working strategy that can be applied to any human membrane protein with prohibiting high  $\Delta E_{\rm open}$  transcripts, by reducing the magnitude to permissive prokaryotic values (figure 4b, green curve). Our results hence suggest that enhancing expression levels via sequence design optimisation by synonymous mutations can be effectively employed in all those other cases where poor mRNA accessibility compromises the outset of translation and hence, reducing protein expression.

## 4. Discussion

The current study demonstrates that prokaryotic cell-free expression of human VDAC is determined by the mRNA sequence in the immediacy of the start codon and its impact on translation initiation. Providing the RBS site is optimal, i.e., 11 nucleotides upstream the ATG codon, the efficiency of protein expression can be enhanced by introducing synonymous mutations in the first 9 codons of the TR. Computer calculations have provided the scoring function  $\Delta E_{\rm open}$  that allows the quantitative assessment of the translation initiation potential for the plasmids herein investigated, and an optimised, enhancer-free DNA sequence that allows the cell-free expression of native VDAC. This computerised approach, publicly available as webservice XenoExpressO at rna.tbi.univie.ac.at., can thus predict the performance of plasmids in cell-free protein expression, and provide the optimised sequence of translatable plasmids for VDAC and other human membrane proteins. One main advantage of this protein expression enhancement strategy is the easy implementation of silent mutations in expression vectors via primer design. Though challenges concerning structure and function of membrane proteins still remain, our study presents a rational approach for an effective go in membrane protein synthesis efficiency.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: List of primer sequences used in this study. Table S2: qPCR VDAC specific primer pairs. Figure S1: MALDI-TOF-MS spectrum of VDAC showing the tryptic peptides. Figure S2: MS/MS spectra of two parent ions corresponding to the two highest peaks of the MS spectrum (figure S1). Figure S3: Western Blots of VDAC expression in E. coli. Figure S4: Coomassie stainings of the constructs VDAC-I (A,B,C) (a) and VDAC-II (A-G) (b). Figure S5: Western Blot showing the level of protein expression for the constructs VDAC-I (I-A, I-B, I-C) and VDAC-II (II-A, II-B, II-C, II-D, II-E, II-F, II-G). Table S3: Number of amino acids and the corresponding molecular weight (MW) of the resulting protein, based on the construct's coding sequence. Figure S6: Average opening energies as a function of i, the RDS location for the E. coli (brown curve) and the H. sapiens (orange curve) genomes.

**Author Contributions:** S.Z. and S.D. contribute equally to this work.

Conceptualization and methodology of this work had been accomplished by Sonja Zayni, Samar Damiati, Fabian Amman, Ivo Hofacker and Eva-Kathrin Ehmoser. The analytical software tool has been published as XenoExpressO at rna.tbi.univie.ac.at by Fabian Amman and Ivo Hofacker. Data validation between *in silico* and experimental results had been jointly performed by Sonja Zayni, Samar Damiati and Fabian Amman. Funding acquisition and administration have been performed by Eva-Kathrin Ehmoser, Fabian Amman and Ivo Hofacker. Writing the original draft preparation, had been accomplished by Sonja Zayni, Samar Damiati, Eva-Kathrin Ehmoser, Fabian Amman and Ivo Hofacker, writing-review and editing Susana Moreno-Flores; visualization, Susana Moreno-Flores and Eva-Kathrin Ehmoser.; All authors have read and agreed to the published version of the manuscript.

**Funding:** FA thanks the Austrian Science Fund (FWF) for its financial support (Project SFB F43). We are acknowledging the Open Access Fond of the University of Natural Resources and Life Sciences, BOKU, Vienna for financial support.

**Acknowledgments:** The authors thank Joel Chopineau for kindly providing the plasmid vector pQE30-VDAC. This open access publication is supported by the BOKU Vienna Open Access Publishing Fund.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

### References

- 1. Jackson AM, Boutell J, Cooley N, He M. Cell-free protein synthesis for proteomics. *Brief Funct Genomic Proteomic*. **2004**; 2, 308-319. DOI 10.1093/bfgp/2.4.308
- 2. Endo Y, Sawasaki T. Cell-free expression systems for eukaryotic protein production. *Curr Opin Biotechnol.* **2006**; 17: 373-380. DOI 10.1016/j.copbio.2006.06.009
- 3. Damiati S, Mhanna R, Kodzius R, Ehmoser EK. Cell-Free Approaches in Synthetic Biology Utilizing Microfluidics. *Genes*, **2018**, *9*, 144. DOI 10.3390/genes9030144
- 4. Damiati S, Zayni S, Schrems A, Kiene E, Sleytr UB, Chopineau J, Schuster B, Sinner EK. Inspired and stabilized by nature: ribosomal synthesis of the human voltage gated ion channel (VDAC) into 2D-proteintethered lipid interfaces. *Biomater Sci.* **2015**, *3*, 1406-1413. DOI 10.1039/c5bm00097a
- Damiati S. "Can we rebuild the Cell Membrane?" in Biological, Physical and Technical Basics of Cell Engineering, G. Artmann, A. Artmann, A. Zhubanova and I. Digel, Eds., Singapore, Springer, 2018,3- 27. DOI: 10.1007/978-981-10-7904-7
- 6. Carlson E, Gan R, Hodgman E, Jewett M. Cell-free protein synthesis: applications come of age. *Biotechnol Adv.* **2012**, 30, 1185-1194. DOI 10.1016/j.biotechadv.2011.09.016
- 7. Na D, Lee S, Lee D. Mathematical modeling of translocation initiation for the estimation of its efficiency to computationally design mRNA sequences with desired expression levels in prokaryotes. *BMC Systems Biology.* **2010**; 4: 71-86. DOI 10.1186/1752-0509-4-71
- 8. Salis HL, Mirsky EA, Voigt CA. Automated design of synthetic ribosome binding sites to control protein expression. *Nat Biotech.* **2009**; *27*(10): 946-950. DOI 10.1038/nbt.1568
- 9. Colombini M. A candidate for the permeability pathway of the outer mitochondrial membrane. *Nature.* **1979**; 279, 643-645. DOI 10.1038/279643a0
- 10. Hiller S, Abramson J, Mannella C, Wagner G, Zeth K. The 3D structures of VDAC represent a native conformation. *Trends Biochem Sci.* **2010**; 35: 514-521. DOI 10.1016/j.tibs.2010.03.005
- 11. Hiller S, Garces RG, Malia TJ, Orekhov VY, Colombini M, Wagner G. Solution structure of the integral human membrane protein VDAC-1 in detergent micelles. *Science*. **2008**; 321: 1206-1210. DOI 10.1126/science.1161302
- 12. Carneiro CM, Krasilnikov OV, Yuldasheva LN, Campos de Carvalho AC, Nogueira RA. Is the mammalian porin channel, VDAC, a perfect cylinder in the high conductance state? *FEBS Letters*. **1997**; 416: 187-189. DOI 10.1016/s0014-5793(97)01198-8
- 13. Goncalves RP, Buzhysnskyy N, Scheuring S. Mini review on the structure and supramolecular assembly of VDAC. *J Bioenerg Biomembr.* **2008**; 40: 133-138. DOI 10.1007/s10863-008-9141-2
- 14. For further details the authors refer to the Supporting Information.
- 15. Lorenz R, Bernhart S H, Höner zu Siederdissen C, Tafer H, Flamm C, Stadler PF, Hofacker IL. ViennaRNA Package 2.0. Algorithms *Mol Biol.* **2011**; *6*: 26-39. DOI 10.1186/1748-7188-6-26
- 16. Mückstein U, Tafer H, Bernhart SH, Hernandez-Rosales M, Vogel J, Stadler PF, Hofacker IL. *Communications in Computer and Information Science, vol. 13*, M. Elloumi, J. Küng, M. Linial, R. Murphy, K. Scheider and C. Toma, Eds., Berlin-Heidelberg: Springer-Verlag, 2008, pp. 114-127. DOI
- 17. Bernhardt SH, Hofacker IL, Stadler PF. Local RNA base pairing probabilities in large sequences. *Bioinformatics*. **2005**; 22: 614-615. DOI
- 18. Coomassie stained gels and a Western Blot of all samples are provided in the Supporting Information

- 19. An exact quantification of synthesized VDAC was not possible due to interference of proteins in the reaction mixture. For details on MS results, the authors refer to the Supporting Information.
- 20. Son JM, Ahn JH, Hwang MY, Park CG, Choi CY, Kim DM. Enhancing the efficiency of cell-free protein synthesis through the polymerase-chain-reaction-based addition of a translation enhancer sequence and the in situ removal of the extra amino acid residues. *Anal. Biochem.* **2006**; 351: 187-192. DOI 10.1016/j.ab.2005.11.047
- 21. The presence of weak bands at 36 kDa in these constructs is attributed to background expression, which is commonplace in cell-free synthesis. For a more detailed discussion, the authors refer to the Supporting Information.
- 22. Kozak M. Initiation of translation in prokaryotes and eukaryotes. *Gene.* **1999**; 234: 187-208. DOI 10.1016/s0378-1119(99)00210-3
- 23. De Smit MH, van Duin J. Secondary structure of the ribosome binding site determines translational efficiency: A quantitative analysis. *Proc Natl Acad Sci USA*. **1990**; *87*: 7668–7672.
- 24. Rogers Jr GW, Komar AA, Merrick WC. eIF4A: the godfather of the DEAD box helicases. *Prog Nuclei Acid Res. Mol. Biol.* 2002; 72: 307-331. DOI 10.1016/s0079-6603(02)72073-4
- 25. Sambrook J, Russell D. Molecular Cloning, Vol. 2, (CHSL Press, New York, 2001, p. 13.87.
- Haluska CK, Riske KA, Marchi-Artzner V, Lehn JM, Lipowsky R, Dimova R. Time scales of membrane fusion revealed by direct imaging of vesicle fusion with high temporal resolution. *Proc Natl Acad Sci.* 2006; 103: 15841-15846. DOI 10.1073/pnas.0602766103
- 27. Morris DR, Geballe AP. Upstream open reading frames as regulators of mRNA translation. *Mol Cell Biol.* **2004**; 20: 8635-8642. DOI 10.1128/MCB.20.23.8635-8642.2000
- 28. Barbosa C, Peixeiro I, Romão L. Gene Expression Regulation by Upstream Open Reading Frames and Human Disease. *PLoS Genetics.* **2013**; 9: e1003529. DOI 10.1371/journal.pgen.1003529
- 29. Schwartz D, Klammt C, Koglin A, Lohr F, Schneider B, Dotsch V, Bernhard F. Preparative scale cellfree expression systems: New tools for the large scale preparation of integral membrane proteins for functional and structural studies. *Methods.* **2007**; *41*: 355-369. DOI 10.1016/j.ymeth.2006.07.001
- 30. The opening energy at i=11 for the E. Coli genome is a local minimum. For further details and results the authors refer to the Supporting Information.
- 31. VDAC-14 constructs can be expressed in cells though in lower quantities than their VDAC-17 counterparts. The authors refer to the Supporting Information.
- 32. Abu-Hamad S, Arbel N, Calo D, Arzoine L, Israelson A, Keinan N, Ben-Romano R, Friedman O, Shoshan-Barmatz V. The VDAC1 N-terminus is essential both for apoptosis and the protective effect of anti-apoptotic proteins. *J Cell Sci.* **2009**; 122:1906-1916. DOI 10.1242/jcs.040188